Personalized, adaptive deep brain stimulation (DBS) can enhance the control of motor symptoms of Parkinson's disease (PD) compared with standard DBS, new research suggests. In a blinded randomized ...
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adaptive ...
DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (MDT) (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's ...
Hosted on MSN
Long-term at-home adaptive deep brain stimulation found to be effective in Parkinson's disease
The Department of Neurology and Neurological Sciences at Stanford University School of Medicine, together with multiple academic medical centers and one industry partner (Medtronic) across the US, ...
Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform
MILAN, Feb. 13, 2025 /PRNewswire/ -- Newronika, a global leader in advanced deep brain stimulation, is pleased to announce the successful closing of its €13.6 million Series B funding round. The ...
Medtronic plc’s Brainsense adaptive deep brain stimulation system has been shown to be tolerable, effective and safe for long-term use at home in people with Parkinson’s disease. A study published in ...
MILAN, Feb. 5, 2025 /PRNewswire/ -- Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an Investigational Device Exemption (IDE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback